artemether / Generic mfg. - LARVOL DELTA

Acute and prolonged effects of anti-malarial drugs on mitochondrial respiration in atrial cardiomyocytes for cardiac safety evaluation. (PubMed, PLoS One) - "These findings provide insights into the effects of anti-malarial drugs on mitochondrial function in cardiomyocytes. Further studies should aim to elucidate the molecular mechanisms underlying these drug-induced mitochondrial effects."

Journal • Cardiovascular • Infectious Disease • Malaria

Artemether alleviates Aβ1-42-induced neuronal cell damage via PGC-1α-mediated mitochondrial homeostasis in Alzheimer's disease. (PubMed, Cell Signal) - "Our findings indicate that neuronal mitochondrial dysfunction serves as a central driver in AD pathogenesis, and activating the PGC1α/ERRα/TFAM axis through artemether offers an effective and feasible strategy for the prevention and treatment of AD."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Inflammation • Metabolic Disorders • TFAM

Repurposing sirolimus as a single and combination therapy for malaria: in silico, in vivo and pharmacokinetic studies. (PubMed, J Parasit Dis) - "Also, co-administration of Sirolimus with Artemether affected the pharmacokinetics profile of dihydroartemisinin. The result suggests that Sirolimus possesses suppressive antiplasmodial potential particularly when administered early in infection, and can be combined with Artemether to increase the curative activity of the latter."

Journal • PK/PD data • Preclinical • Infectious Disease • Malaria • Oncology

Formulation and Optimization of Artemether-Loaded Nanoemulsions by Applying QbD. (PubMed, Pharmaceuticals (Basel)) - " The optimized Artemether-loaded nanoemulsion, developed using a Box-Behnken Design, significantly enhanced the drug's dissolution and exhibited favorable physicochemical characteristics, high entrapment efficiency, and controlled release behavior. These findings suggest that nanoemulsion is a promising carrier system warranting further in vivo evaluation to confirm its potential for improving the oral bioavailability of Artemether."

Journal • Infectious Disease

Artemisia annua and Its Derivatives Improve the Refrigerated Shelf Life of Nile Tilapia Fillets. (PubMed, Foods) - "Artemether showed the most pronounced benefits, with lower microbial loads and oxidation indices for several evaluated parameters. These findings suggest that dietary supplementation with A. annua and its derivatives may help delay post-harvest quality deterioration of tilapia fillets during refrigerated storage."

Journal

Preparation, characterization and pre-clinical evaluation of artemether-lumefantrine-paracetamol (AL-P) loaded nanocarriers in the treatment of malaria. (PubMed, Malar J) - "ALP SLNs demonstrated favorable physicochemical properties, a satisfactory safety profile in acute and sub-acute preclinical testing, and superior antiplasmodial efficacy and a highly effective delivery system for malaria triple therapy compared to free drugs. These findings highlight their potential in overcoming malaria treatment challenges, hence supporting further pharmacokinetic and translational studies toward clinical evaluation."

Journal • Preclinical • Infectious Disease • Malaria

Improved protocols using sodium artesunate for the treatment of experimental cerebral malaria. (PubMed, Antimicrob Agents Chemother) - "Artemether and artesunate are effective antimalarial drugs in rescue therapies of Plasmodium berghei ANKA (PbA)-infected mice with experimental cerebral malaria (ECM), with a superiority for artemether among the single daily dosing schemes...Infected mice on 5 dpi showed severe thrombocytopenia (196 ± 118.3 platelets/μL; uninfected controls: 1,291 ± 256.4 platelets/μL), and artesunate treatment had little impact on these numbers 24 h after the first dose. In conclusion, two daily doses IP or via slow continuous delivery improve the efficacy of artesunate treatments compared to single-daily dose schemes and are suitable for ECM adjunctive therapy studies."

Journal • Hematological Disorders • Infectious Disease • Malaria • Thrombocytopenia

Research Progress on Anti-Inflammatory and Antioxidant Mechanism of Artemether Based on MAPK/NF-κB Signaling Pathway. (PubMed, Int J Mol Sci) - "Compared to conventional NSAIDs and glucocorticoids, artemether exhibits a favorable safety profile, particularly regarding gastrointestinal effects, and demonstrates unique immunomodulatory potential. Future research directions should prioritize the development of nano-targeted delivery systems and the elucidation of pathway crosstalk at the single-cell level to advance the clinical translation of artemether for chronic inflammatory diseases."

Journal • Review • CNS Disorders • Immunology • Inflammation • Rheumatology • IL6 • NFKBIA • TNFA

Why are iron chelators not as effective as artemisinin in killing malaria parasites? (PubMed, Parasit Vectors) - "Artemisinin and its derivatives exhibit more potent antimalarial activity than iron chelators, likely stemming from their ability to accumulate in the parasite's digestive vacuoles, interact more effectively with heme and iron, and thereby disrupt heme/iron homeostasis and utilization."

Journal • Infectious Disease • Malaria

Efficacy and safety of praziquantel combined with artemisinin derivatives versus praziquantel monotherapy for schistosomiasis: a meta-analysis of randomized controlled trials. (PubMed, Infection) - "The combination of PZQ and ARTs can significantly improve the CR for S. mansoni, but not for other schistosome species, at the cost of a higher incidence of adverse events, which were however manageable."

Journal • Monotherapy • Retrospective data • Infectious Disease • Malaria

Artemether ameliorates type 1 diabetic liver injury alongside the associated defects in mitochondrial ultrastructure and central carbon metabolism. (PubMed, PLoS One) - "Importantly, Art preserved mitochondrial morphology, restored the expression of some proteins related to the respiratory chain complex, and downregulated indicators of hepatic fatty acid β-oxidation, upregulated markers of de novo fatty acid synthesis, normalized intrahepatic triglyceride concentrations, and reduced expression of key molecules involved in gluconeogenesis and glycogenolysis. These findings indicate that Art confers protective effects against liver injury in T1DM through coordinated modulation of mitochondrial function and key metabolic pathways at transcriptional, translational, and metabolic intermediate levels."

Journal • Diabetes • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Type 1 Diabetes Mellitus

Artemether and Euphorbia Factor L9 suppress kynurenine production through distinct effects on Tryptophan metabolism. (PubMed, Biochem J) - "Notably ouabain, a regulator of IDO1 levels, and Linrodostat, a clinically approved IDO1 inhibitor, revealed distinct metabolic profiles, with ouabain and EFL9 showing the largest overlap. Importantly, the kynurenine-suppressing activities of artemether and EFL9 were observed in non-transformed primary mammary epithelial cells and also lung cancer cells. Overall, our findings set the foundation for future studies exploring the use of artemether or EFL9 as novel Trp metabolism-targeting therapeutics."

Journal • Breast Cancer • Infectious Disease • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor • Triple Negative Breast Cancer

Artemether as a modulator of EMT in colorectal cancer: enhancing radiosensitivity and reversing chemo-radiation resistance. (PubMed, BMC Gastroenterol) - "These findings provide both mechanistic insights and experimental validation for the potential application of ARE as a radiosensitizer in colorectal cancer radiotherapy."

Journal • Colorectal Cancer • Oncology • Solid Tumor • Transplantation • CDH1 • CDH2 • CTNNB1 • SNAI2 • VIM

Successful treatment of severe cerebral malaria with artificial liver blood purification technology: A case report. (PubMed, Medicine (Baltimore)) - "The integration of artificial liver blood purification with continuous renal replacement therapy may serve as an effective rescue therapy for severe malaria with multi-organ failure, potentially by mitigating the systemic inflammatory response and supporting organ recovery. This case highlights the potential of combined extracorporeal support in managing critical tropical infections."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Liver Failure • Malaria • Nephrology • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Septic Shock • Systemic Inflammatory Response Syndrome • Thrombocytopenia

Anti-Theileria equi activity of methanolic extract of Artemisia scoparia: In vitro efficacy, in vivo safety, and identification of lead molecules. (PubMed, Vet Parasitol) - "HPLC and LC-MS/MS analyses identified 17 bioactive compounds in MF-ASME, with artemisinin, artemether, and dihydroartemisinin as the primary antimalarial agents. These results support the potential of MF-ASME for further therapeutic development against equine theileriosis."

Journal • Preclinical • Infectious Disease

Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation. (PubMed, Biochem Pharmacol) - "Through a high-throughput screen of FDA-approved compounds, artemether (ART) emerged as a robust inducer of PD-L1 surface expression in multiple murine and human TNBC cell lines. Critically, in syngeneic TNBC mouse models, ART synergistically enhanced the antitumor efficacy of atezolizumab, promoting tumor regression and increasing intratumoral CD8+ T cell infiltration and cytotoxicity. Our findings reveal a novel mechanism by which ART upregulates PD-L1 through KEAP1 inhibition and establish ART as a promising pharmacological agent to improve the clinical outcomes of PD-L1 checkpoint blockade immunotherapy in TNBC."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • Triple Negative Breast Cancer • CD8 • KEAP1 • PD-L1

Effect of artesunate and artemether against Opisthorchis felineus in rodent model. (PubMed, Acta Trop) - "A comparative in vivo assessment of the artemisinin derivatives artesunate and artemether (150 and 300 mg/kg) and praziquantel (400 mg/kg) was conducted in a hamster model of opisthorchiasis caused by Opisthorchis felineus. Administration of artesunate and artemether at both doses normalized platelet, eosinophil, and basophil counts in infected animals. The results indicate that artemisinin derivatives may serve as promising alternatives for the treatment of O. felineus opisthorchiasis and warrant further preclinical and clinical evaluation."

Journal • Preclinical • Hematological Disorders • Infectious Disease

Artemether Attenuates High Glucose-Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF-β/Smad Pathway Via PPARγ Activation. (PubMed, J Diabetes Res) - "In conclusion, our study indicates that Art protects renal tubular epithelial cells by partially modulating PPARγ-dependent inhibition of the TGF-β/Smad pathway, thereby mitigating HG-induced inflammation and fibrosis. These findings suggest that Art holds promising therapeutic potential for DKD treatment."

Journal • Diabetes • Diabetic Nephropathy • Fibrosis • Immunology • Infectious Disease • Inflammation • Malaria • Nephrology • Oncology • Renal Disease • IL1B • IL6 • PPARG • TGFB1 • TNFA

Artemisinin and its derivatives: all-rounders that may prevent the progression from lung injury to lung cancer. (PubMed, Front Pharmacol) - "Specifically, in phase of inflammation and injury (phase Ⅰ), artesunate, dihydroartemisinin, and artemether alleviate the symptoms of pneumonia and lung injury by regulating inflammatory responses, oxidative stress, apoptosis, and endoplasmic reticulum stress...Additionally, current research is focused on nanoscale delivery systems to increase the bioavailability and improve drug stability, to enhance the therapeutic efficacy of these compounds. Collectively, artemisinin and its derivatives are the potential clinically useful therapeutic agents for protecting lungs and hampering the dynamic development processes of lung diseases to lung cancer."

Journal • Review • Chronic Obstructive Pulmonary Disease • Fibrosis • Immunology • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • KEAP1

Comparative effects of antimalarial drugs on oxidative phosphorylation, mitochondrial dynamics and mitophagy in Plasmodium berghei-infected mice. (PubMed, Toxicol Rep) - "Thirty-five Swiss-mice (18 ± 3 g) were infected intraperitoneally with chloroquine resistant (ANKA) strain of Plasmodium berghei and treated orally and once daily with (10 mg/kg) dose of Amodiaquine artesunate (AA), Artemether-Lemefantrine (AL), Sulfadoxine- pyrimethamine (SP) and Artesunate (ART), On day 6, animals were sacrificed and livers were removed. Significant down-regulation in the expressions of PINK 1 by SP, FUNDC1 by AA and AL, DNM1L by ART, PGC-1α by AA, AL, and ART, and prohibitins 1 and 2 by AA and AL similar to the infected control were observed. This study showed that host mitochondria respond differently to antimalarial drugs."

Journal • Preclinical • Infectious Disease • MFN2

The contrasting effects of two antimalarial drugs on insulin secretion. (PubMed, Cell Mol Life Sci) - "In particular, artemether significantly suppressed insulin secretion, decreased Ca2+ influx and the expression levels of β-cell marker genes, contradicting the findings of previous studies suggesting that artemisinins promote the transformation of pancreatic α cells into β cells. Overall, our observations revealed the differential effects of two widely used antimalarial drugs, quinolines and artemisinins, on insulin secretion. Ascertaining the targets by which drugs affect insulin secretion may advance diabetes treatment."

Journal • Diabetes • Hypoglycemia • Infectious Disease • Malaria • Metabolic Disorders

Anti-Inflammatory Efficacy of a Functional Shampoo Mixed With 0.063% Artemether for Seborrheic Dermatitis. (PubMed, J Cosmet Dermatol) - No abstract available

Journal • Dermatitis • Dermatology • Immunology • Seborrheic Dermatitis

β-Dystroglycan Downregulation and Astrocytic Alterations: A Possible Role in Blood-Brain Barrier Disruption During Experimental Cerebral Malaria. (PubMed, Mol Neurobiol) - "Early treatment with artemether (ARM) was conducted to monitor the recovery during pathology...Furthermore, immunohistochemical analysis revealed loss of β-dystroglycan (β-DG), altered astrocyte morphology, and reduced tight junction protein zonula occludens-1 (ZO-1) and collagen IV expression during disease. In summary, these results suggested that β-DG cleavage by matrix metalloproteinase-9 (MMP-9) results in the disruption of astrocytic cellular connection with vasculature, and when dystrophin-glycoprotein complex (DGC) proteins are dysregulated, it leads to the development of edema."

Journal • CNS Disorders • Infectious Disease • Malaria • MMP9 • TJP1

Pharmacogenomics in Orofacial Clefts Care: Insights from Whole-Genome Sequencing of Case-Parents Trios. (PubMed, J Pers Med) - "The identified variations were linked to the metabolism of frequently used pharmaceuticals in Africa, such as caffeine, ketoconazole, efavirenz, carbamazepine, and artemether. These findings highlight the need for pharmacogenetic screening to inform personalized medicine, diminish ADRs, and enhance the clinical care of OFCs in Sub-Saharan Africa."

Biomarker • Journal • ABCC3 • CYP1A2 • CYP27A1

Identification of a novel locus associated with decreased susceptibility of Plasmodium falciparum to lumefantrine and artemisinin in Uganda (ASTMH 2025) - "The most common artemisinin-based combination (ACT), artemether-lumenantrine, is threatened in Uganda, where multiple artemisinin partial resistance (ART-R) mutations in Kelch13 (K13), including the C469Y and A675V mutations, are spreading, and decreasing lumefantrine (LUM) susceptibility has been demonstrated...PIN-carrying isolates showed significantly decreased ex vivo susceptibility to LUM, mefloquine and dihydroartemisinin (DHA) compared to WT (P<0.0001 for each drug). The newly identified PIN haplotype represents a candidate marker for decreased susceptibility to DHA and/or LUM. Its rapid spread in Uganda underscores the importance of evaluating its distribution and role in the emergence of ART-R elsewhere in East Africa."

Late-breaking abstract • Infectious Disease